Intrarenal renin-angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis

Journal of the American Society of Nephrology

Volumn 15, Issue 7, 2004, Pages 1805-1815

  Graciano, Miguel Luis ^a   Cavaglieri, Rita De Cassia ^a   Dellê, Humberto ^a   Dominguez, Wagner Vasquez ^a   Casarini, Dulce Elena ^b   Malheiros, Denise Maria Avancini Costa ^a   Noronha, Irene L ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; LOSARTAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; RENIN;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY COLLECTING TUBULE; KIDNEY DISEASE; KIDNEY INTERSTITIUM; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 3042570225     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000131528.00773.A9     Document Type: Article

References (46)

1. Quan A, Boum M: Endogenous production of angiotensin II modulates rat proximal tubule transport. J Clin Invest 97: 2878-2882, 1996
2. Wang T, Giebsch G: Effects of angiotensin II on electrolyte transport in the early and late distal tubule in rat kidney. Am J Physiol 271: F143-F149, 1996
3. Noronha IL, Fujihara CK, Oliveira IB, Leitao TG, Zatz R: Enhanced interstitial expression of angiotensin II and TGF-β in the renal ablation model: Effect of mycophenolate mofetil. J Am Soc Nephrol 9: 618, 1998
4. Quiroz Y, Pons H, Gordon KL, Rincón J, Chávez M, Parra G, Herrera-Acosta J, Gómez-Garre, Largo R, Egido J, Johnson RJ, Rodríguez-Iturbe: Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition. Am J Physiol 281: F38-F47, 2001
5. Mackenzie HS, Troy JL, Rennke HG, Brenner BM: TCV 116 prevents progressive renal injury in rats with extensive renal mass ablation. J Hypertens Suppl 12: S11-S16, 1994
6. Anderson S, Meyer TW, Rennke HG, Brenner BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76: 612-619, 1985
7. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin converting enzyme inhibition in progressive renal insufficiency study group. N Engl J Med 334: 939-945, 1996
8. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462, 1993
9. Weidmann P, Schneider M, Bohlen L: Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: An updated meta-analysis. Nephrol Dial Transplant 10[Suppl 9]: 39-45, 1995
10. Wu LL, Cox A, Roe CJ, Dziadek M, Cooper ME, Gilbert RE: Transforming growth factor β1 and renal injury following subtotal nephrectomy in the rat: Role of the renin-angiotensin system. Kidney Int 51: 1553-1567, 1997
11. Wolf G, Haberstroh U, Neilson EG: Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 140: 95-107, 1992
12. Peters H, Border WA, Noble NA: Targeting TGF-beta overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 54: 1570-1580, 1998
13. Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A: Modulation of plasminogen activator inhibitor-I in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 51: 164-72, 1997
14. Nishiyama A, Seth DM, Navar LG: Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension 39: 129-134, 2002
15. Danser AH, Saris JJ, Schuijt MP, van Kats JP: Is there a local renin-angiotensin system in the heart? Cardiovasc Res 44: 252-265, 1999
16. Warnock DG: Prevention, protection, and the intrarenal renin-angiotensin systems. Semin Nephrol 21: 593-602, 2001
17. Braam B, Mitchell KD, Fox J, Navar LG: Proximal tubular secretion of angiotensin 11 in rats. Am J Physiol 264: F891-F898, 1993
18. Morris BJ, Reid IA: A "renin-like" enzymatic action of cathepsin D and the similarity in subcellular distributions of "renin-like" activity and cathepsin D in the midbrain of dogs. Endocrinology 103: 1289-1296, 1978
19. Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, Zatz R: Chronic inhibition of nitric oxide synthesis - A new model of arterial hypertension. Hypertension 20: 298-303, 1992
20. Baylis C, Harton P, Engels K: Endothelial derived relaxing factor controls renal hemodynamics in the normal rat kidney. J Am Soc Nephrol 1: 875-881, 1990
21. Fujihara CK, Michellazzo SM, de Nucci G, Zatz R: Sodium excess aggravates hypertension and renal parenchimal injury in rats with chronic NO inhibition. Am J Physiol 266: F697-F705, 1994
22. Fujihara CK, Malheiros DMAC, Noronha IL, De Nucci G, Zatz R: Mycophenolate mofetil reduces renal injury in the chronic nitric oxide synthase inhibition model. Hypertension 37: 170-175, 2001
23. Haber E, Koerner T, Page LB, Kliman B, Purnod A: Application of radioimmunoassay for angiotensin I to the physiologic measurement of plasma renin activity in normal human subjects. J Clin Endocrinol Metab 29: 1359-1355, 1969
24. Nussberger J, Brunner DB, Waeber B, Brunner HR: True versus immunoreactive angiotensin II in human plasma. Hypertension 7[Suppl 1]:I1-I7, 1985
25. Oliveira EM, Santos RA, Krieger JE: Standardization of a fluorometric assay for the determination of tissue angiotensin-converting enzyme activity in rats. Braz J Med Biol Res 33: 755-64, 2000
26. Arnal JF, Warin L, Michel JB: Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J Clin Invest 90: 647-652, 1992
27. Pollock DM, Polakowski JS, Divish BJ, Opgenorth TJ: Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition. Hypertension 21: 660-666, 1993
28. Qiu C, Muchant D, Beierweltes LR, Baylis C: Evolution of chronic oxide inhibition of hypertension: Relationship to renal function. Hypertension 31: 21-26, 1998
29. Ingert C, Grima M, Coquard C, Barthelmebs M, Imbs JL: Effects of dietary salt changes in renal renin-angiotensin system in rats. Am J Physiol 283: F995-F1002, 2002
30. Bouhnik J, Richoux JP, Huang H, Savoie F, Baussant T, Alhenc-Gelas F, Corvol P: Hypertension in Dahl salt-sensitive rats: Biochemical and immunohistochemical studies. Clin Sci 83: 13-22, 1992
31. Kobori H, Harrison-Bernard LM e Gabriel Navar L: Expression of angiotensinogen mRNA and protein in angiotensin II-dependent hypertension. J Am Soc Nephrol 12: 431-439, 2001
32. Largo R, Gómez-Garre D, Soto K, Marron B, Blanco J, Gazapo RM, Plaza JJ, Egido J: Angiotensin-converting enzyme is up-regulated in the proximal tubules of rats with intense proteinuria. Hypertension 33: 732-739, 1999
33. Rohrwasser A, Morgan T, Dillon HF, Zhao L, Callaway CW, Hillas E, Zhang S, Cheng T, Inagami T, Ward K, Terreros DA, Lalouel JM: Elements of a paracrine tubular renin-angiotensin system along the entire nephron. Hypertension 34: 1265-1274, 1999
34. Gilbert RE, Wu LL, Kelly DJ, Cox A, Wilkinson-Berka JL, Johnston CI, Cooper ME: Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis. Am J Pathol 155: 429-440, 1999
35. Kobori H, Harrison-Bernard LM, Gabriel Navar L: Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney Int 61: 579-585, 2002
36. Metzger R, Bohle RM, Pauls K, Eichner G, Alhenc-Gelas F, Danilov SM, Franke FE: Angiotensin-converting enzyme in non-neoplastic kidney diseases. Kidney Int 56: 1442-1454, 1999
37. Marcic B, Deddish PA, Jackman HL, Erdös EG, Tan F: Effects of the N-terminal sequence of ace on the porperties of its C-domain. Hypertension 36: 116-121, 2000
38. Kashiwagi M, Shinozaki M, Hirataka H, Tamaki K, Hirano T, Tokumoto M, Goto H, Okuda S, Fujishima M: Locally activated renin-angiotensin system associated with TGF-beta1 as a major factor for renal injury induced by chronic inhibition of nitric oxide synthase in rats. J Am Soc Nephrol 11: 616-24, 2000
39. Fox J, Guan S, Hymel AA, Navar LG: Dietary Na and ACE inhibition effects on renal tissue angiotensin I and II and ACE activity in rats. Am J Physiol 262: F902-F909, 1992
40. Graciano M, Cavaglieri R, Dominguez W, Delle H, Noronha I: Renal myofibroblasts produce angiotensin II: Upregulation induced by IL-1β. Nephrol Dial Transplant 18[Suppl 4]: 584, 2003
41. Yamada SS, Sassaki AL, Fujihara CK, Malheiros DM, De Nucci G, Zatz R: Effect of salt intake and inhibitor dose on arterial hypertension and renal injury induced by chronic nitric oxide blockade. Hypertension 27: 1165-1172, 1996
42. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, and Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor on non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 36I: 117-124, 2003
43. Fujihara CK, Malheiros DM, Zatz R, Noronha ID: Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 54: 1510-1519, 1998
44. Antonipillai I: Tumor necrosis factor and interleukin-1 may regulate renin secretion. Endocrinology 126: 273-278, 1990
45. Brasier AR, Li J: Mechanisms for inducible control of angiotensinogen gene transcription. Hypertension 27: 465-475, 1996
46. Klett C, Hellmann W, Ganten D, Hackenthal E: Tissue distribution of angiotensinogen mRNA during experimental inflammation. Inflammation 17: 183-197, 1993